Skip to main content
. Author manuscript; available in PMC: 2014 Sep 4.
Published in final edited form as: Gene Ther. 2011 Feb 10;18(6):606–612. doi: 10.1038/gt.2011.5

Figure 6.

Figure 6

Comparison of FL activity in both tumor and normal liver after either systemic or intratumoral injection of pSurv-TSTA-TRAIL-FL virus. (a) Although both systemic and intratumoral injection resulted in notable tumor specificity using the Survivin-targeted system, as expected direct intratumoral delivery (right image) resulted in visibly greater FL activity within tumors (white arrow) compared with intravenous delivery. The scale bar is the same for both images to highlight differences in expression levels. (b) Analysis of BLI images revealed significantly improved tumor/liver ratio of FL activity (mean±s.e.m.) following intratumoral (n=3) versus systemic (n=5) viral administration. *P<0.05 as determined via two-tailed, unpaired t-test.